Hydroxocobalamin

羟钴胺

Report date: 2026/02/11 20:01:36
NME

Base Information

Drug NameHydroxocobalamin
Drug Alias Name羟钴胺造血维生素Hydroxocobalaminum维生素B12B羟基钴胺素羟钴胺素 +[9] 
ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsMethylmalonic acidaemiaPoisoningVitamin B 12 Deficiency +[11] 
Global Approved IndicationsPoisoningVitamin B 12 DeficiencyAnemia, Pernicious +[5] 
Approved Indications in ChinaVitamin B 12 DeficiencyAnemia, PerniciousAnemia, Megaloblastic +[4] 
Original Approved Country/TerritoryUnited States
Original Approved Date1975/04/18
Country/TerritoryUnited StatesNetherlandsEgypt +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdSerb Sa LtdBtg International Inc +[7] 
Inactive CompaniesAriston Pharmaceuticals Inc
Active IndicationsMethylmalonic acidaemiaPoisoningVitamin B 12 Deficiency +[8] 
Inactive IndicationsMigraine without AuraMigraine with AuraMigraine Disorders

Other Information

ATC CodeB03BA03V03AB33
Related LinksWikipediaDrugBankKEGG